Dermatitis News

Colloidal oatmeal 1%, a natural and affordable cream, is just as effective as prescription barrier cream in the treatment of mild to moderate atopic dermatitis in Black children, according to a study.

The FDA has issued a complete response letter for Eli Lilly and Company’s lebrikizumab biologics license application for moderate to severe atopic dermatitis treatment, according to a manufacturer-issued press release.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

Arcutis has launched an educational campaign for people living with seborrheic dermatitis that features expert advice from leading dermatologists and personal stories, according to a company press release.

Roflumilast cream 0.05% achieved positive results in a pediatric trial of a phase 3 program treating children aged 2 to 5 years with mild to moderate atopic dermatitis, according to an Arcutis Biotherapeutics press release.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the marketing authorization of Ebglyss for atopic dermatitis in patients aged 12 years and older, according to an Almirall press release.

Atopic dermatitis is an inflammatory skin disease that affects a significant population worldwide. According to the American Academy of Dermatology, it occurs most frequently in children but also impacts as many as 16.5 million adults.

In honor of World Atopic Eczema Day, Almirall announced the launch of its atopic dermatitis awareness campaign, “Moving aheAD,” according to a company press release.

Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for roflumilast cream 0.15% for mild to moderate atopic dermatitis treatment in adults and children aged 6 years and older, according to a press release.

Arcutis Biotherapeutics announced interim results of its phase 3, long-term extension trial of roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older, according to a press release.